Article Figures & Data
Figures
- FIGURE 1.
(A) Direct procedure. Conjugation of antibody (R-Lys-NH2) with m-MeATE and labeling of conjugated antibody. (B) Conventional procedure. Labeling of m-MeATE followed by conjugation of labeled reagent to antibody (R-Lys-NH2). SAB = N-succinimidyl 3-astatobenzoate.
- FIGURE 2.
Tissue distribution of 211At after injection of 211At-trastuzumab labeled by direct procedure (□) and by conventional 2-step procedure (). Results are given as mean ± SD %IA/g. *Statistically significant difference (P < 0.05), as determined by Student t test.
Tables
- TABLE 2
Tissue Distribution Ratios After Coinjection in Mice of 211At-Trastuzumab Labeled by Direct Procedure and 125I-Trastuzumab Labeled by Conventional Procedure
Tissue distribution ratio* at: Tissue 1 h 3 h 6 h 11 h 24 h Blood 0.98 ± 0.04 0.97 ± 0.02 0.96 ± 0.03 0.94 ± 0.02 0.89 ± 0.02 Neck 1.10 ± 0.04 1.18 ± 0.05 1.50 ± 0.15 1.15 ± 0.13 1.44 ± 0.21 Salivary gland 1.17 ± 0.04 1.29 ± 0.05 1.30 ± 0.03 1.25 ± 0.12 1.28 ± 0.13 Heart 1.06 ± 0.04 1.08 ± 0.03 1.06 ± 0.02 0.99 ± 0.02 0.97 ± 0.02 Lung 1.11 ± 0.05 1.14 ± 0.02 1.19 ± 0.06 1.09 ± 0.05 1.03 ± 0.08 Liver 1.03 ± 0.03 0.90 ± 0.09 0.95 ± 0.04 0.92 ± 0.08 0.78 ± 0.05 Stomach 1.29 ± 0.08 1.72 ± 0.07 2.36 ± 0.30 2.84 ± 0.66 1.88 ± 0.52 Small intestine 1.05 ± 0.05 1.03 ± 0.03 1.09 ± 0.06 1.03 ± 0.02 0.93 ± 0.09 Large intestine 1.06 ± 0.08 1.09 ± 0.02 1.13 ± 0.05 0.93 ± 0.03 0.93 ± 0.03 Kidney 1.00 ± 0.05 1.07 ± 0.01 1.09 ± 0.02 1.04 ± 0.01 0.98 ± 0.03 Muscle 1.05 ± 0.02 1.09 ± 0.02 1.09 ± 0.03 0.89 ± 0.08 0.87 ± 0.05 Spleen 1.03 ± 0.10 1.02 ± 0.11 1.13 ± 0.12 1.02 ± 0.06 0.83 ± 0.06 ↵* Results are given as mean ± SD (%IA/g for 211At/%IA/g for 125I) for 4 animals at each time point.
- TABLE 3
Tissue Distribution Ratios After Coinjection in Mice of 211At-Trastuzumab and 125I-Trastuzumab Labeled by Conventional Procedure
Tissue distribution ratio* at: Tissue 1 h 3 h 6 h 11 h 24 h Blood 0.92 ± 0.02 0.91 ± 0.01 0.98 ± 0.04 1.01 ± 0.02 0.96 ± 0.02 Neck 1.03 ± 0.03 1.11 ± 0.08 1.40 ± 0.12 1.13 ± 0.07 1.48 ± 0.15 Salivary gland 1.14 ± 0.10 1.15 ± 0.11 1.28 ± 0.04 1.16 ± 0.07 1.18 ± 0.05 Heart 0.99 ± 0.01 0.98 ± 0.09 1.03 ± 0.04 1.02 ± 0.03 0.98 ± 0.03 Lung 1.03 ± 0.01 1.04 ± 0.03 1.11 ± 0.04 1.12 ± 0.05 1.06 ± 0.05 Liver 0.87 ± 0.03 0.87 ± 0.09 0.81 ± 0.03 0.84 ± 0.05 0.85 ± 0.06 Stomach 1.34 ± 0.06 2.03 ± 0.25 1.85 ± 0.18 2.12 ± 0.33 1.62 ± 0.15 Small intestine 0.99 ± 0.01 0.97 ± 0.03 0.97 ± 0.05 0.94 ± 0.09 0.94 ± 0.03 Large intestine 1.03 ± 0.05 1.06 ± 0.05 1.06 ± 0.06 0.93 ± 0.07 0.92 ± 0.08 Kidney 0.93 ± 0.01 0.96 ± 0.02 1.02 ± 0.02 1.03 ± 0.03 1.01 ± 0.01 Muscle 1.04 ± 0.05 1.08 ± 0.09 1.11 ± 0.04 0.96 ± 0.06 0.97 ± 0.04 Spleen 0.98 ± 0.05 0.98 ± 0.07 0.80 ± 0.04 0.82 ± 0.11 0.92 ± 0.08 ↵* Results are given as mean ± SD (%IA/g for 211At/%IA/g for 125I) for 4 animals at each time point.
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Harnessing {alpha}-Emitting Radionuclides for Therapy: Radiolabeling Method Review
- Intraperitoneal {alpha}-Emitting Radioimmunotherapy with 211At in Relapsed Ovarian Cancer: Long-Term Follow-up with Individual Absorbed Dose Estimations
- Evidence of Local Concentration of {alpha}-Particles from 211At-Labeled Antibodies in Liver Metastasis Tissue
- Model of Intraperitoneal Targeted {alpha}-Particle Therapy Shows That Posttherapy Cold-Antibody Boost Enhances Microtumor Radiation Dose and Treatable Tumor Sizes
- Cure of Human Ovarian Carcinoma Solid Xenografts by Fractionated {alpha}-Radioimmunotherapy with 211At-MX35-F(ab')2: Influence of Absorbed Tumor Dose and Effect on Long-Term Survival
- The Advantage of Antibody Cocktails for Targeted Alpha Therapy Depends on Specific Activity
- Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the {alpha}-Camera Technique
- Intraperitoneal {alpha}-Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study